Organisation paid for research Program year 2025 Source: CMS Open Payments

Bioresearch Partner

Neither a doctor nor a teaching hospital

Research payments

$177,600

15 payments

Through program year 2025, Bioresearch Partner is reported as receiving $177,600 in research payments, across 15 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$167,910	11
2024	Research	$9,690	4

Breakdown

Who paid Research payments · program years 2024–2025

Vertex Pharmaceuticals Incorporated $75,093 1 payment
Royal Biologics $55,275 11 payments
Merck Sharp & Dohme Corporation $47,232 3 payments

Studies the money was for Research payments · program years 2024–2025

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy $75,093 1 payment
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone $45,585 7 payments
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl $26,016 1 payment
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2,3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma $10,608 1 payment
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors $10,608 1 payment
A Randomized Controlled Multicenter Trial, Examining the Effect of Derm-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers $9,690 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.